Solid Biosciences shares fall after gene therapy trial data

Solid Biosciences experienced a significant drop in its stock price following disappointing data from its gene therapy trial. The trial results did not meet market expectations, leading to concerns over the viability of the company's lead product. Investors are reacting negatively, reflecting uncertainty about the company's future in the competitive gene therapy landscape. Analysts suggest this outcome could hamper future funding and development efforts. As such, Solid Biosciences may face increasing pressure in the biotech sector.